Past performance does not predict future results. Informational only, not investment advice.
Author is bullish on Tandem Diabetes' competitive positioning in the insulin pump market, particularly the PayGo 2027 projections and upcoming Mobi tubeless pump with superior algorithm relative to competitors. Betting on multi-month hold of 70k shares at $17/share ($1.2M position).
Tandem Diabetes has strong Q2 earnings with pay-go system traction and a tubeless pump FDA approval expected before end of year, which should open a new market. Analyst with 85% profitability rating has set a $55 price target.
Tandem Diabetes is transitioning to a SaaS-like PayGo model that doubles recurring revenue per patient while improving margins and cash flow trajectory toward 2027 positivity. The company earns its current market cap in annual revenue with limited competition, making it a compelling M&A target for PE/strategic buyers or a multi-bagger if it executes independently.
End of results.